PE20211756A1 - FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß - Google Patents

FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß

Info

Publication number
PE20211756A1
PE20211756A1 PE2021000893A PE2021000893A PE20211756A1 PE 20211756 A1 PE20211756 A1 PE 20211756A1 PE 2021000893 A PE2021000893 A PE 2021000893A PE 2021000893 A PE2021000893 A PE 2021000893A PE 20211756 A1 PE20211756 A1 PE 20211756A1
Authority
PE
Peru
Prior art keywords
polymorphic forms
tgfß
inhibitor
novel polymorphic
relates
Prior art date
Application number
PE2021000893A
Other languages
English (en)
Inventor
Anand Venkataramana Sistla
Iain David Roy
Andrew Robbins
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20211756A1 publication Critical patent/PE20211756A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/18—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invencion se refiere a formas amorfas y polimorficas cristalinas novedosas de 4-(2-(5-cloro-2-fluorofenil)-5-isopropilpiridin-4-ilamino)-N-(1,3- dihidroxipropan-2-il)nicotinamida y a metodos para su preparacion; la invencion tambien se refiere a composiciones farmaceuticas que contienen al menos una forma polimorfica y al uso terapeutico o profilactico de tales composiciones y formas polimorficas. Este compuesto es util en el tratamiento de crecimiento celular anormal, tal como cancer, en mamiferos
PE2021000893A 2018-12-20 2019-12-17 FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß PE20211756A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782411P 2018-12-20 2018-12-20
US201962930170P 2019-11-04 2019-11-04
PCT/IB2019/060944 WO2020128850A1 (en) 2018-12-20 2019-12-17 Novel polymorphic forms of a tgfβ inhibitor

Publications (1)

Publication Number Publication Date
PE20211756A1 true PE20211756A1 (es) 2021-09-07

Family

ID=69159846

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000893A PE20211756A1 (es) 2018-12-20 2019-12-17 FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß

Country Status (20)

Country Link
US (1) US20200199104A1 (es)
EP (1) EP3898591A1 (es)
JP (1) JP2022513925A (es)
KR (1) KR20210104808A (es)
CN (1) CN113272279A (es)
AU (1) AU2019404250B2 (es)
BR (1) BR112021010577A2 (es)
CA (1) CA3123829A1 (es)
CL (1) CL2021001602A1 (es)
CO (1) CO2021007875A2 (es)
CR (1) CR20210334A (es)
EC (1) ECSP21044734A (es)
IL (1) IL284226A (es)
MA (1) MA54526A (es)
MX (1) MX2021007251A (es)
PE (1) PE20211756A1 (es)
SG (1) SG11202105763SA (es)
TW (1) TWI743631B (es)
UY (1) UY38517A (es)
WO (1) WO2020128850A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022130206A1 (en) * 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
CN112843058A (zh) * 2021-01-27 2021-05-28 复旦大学附属华山医院 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用
WO2022229846A1 (en) * 2021-04-29 2022-11-03 Pfizer Inc. Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3089971T (pt) 2014-01-01 2020-09-03 Medivation Tech Llc Compostos e métodos de utilização

Also Published As

Publication number Publication date
KR20210104808A (ko) 2021-08-25
US20200199104A1 (en) 2020-06-25
CA3123829A1 (en) 2020-06-25
AU2019404250A1 (en) 2021-07-01
BR112021010577A2 (pt) 2021-08-24
MX2021007251A (es) 2021-07-15
CO2021007875A2 (es) 2021-07-19
CL2021001602A1 (es) 2022-01-21
ECSP21044734A (es) 2021-07-30
MA54526A (fr) 2022-03-30
AU2019404250B2 (en) 2022-12-22
TW202039462A (zh) 2020-11-01
CR20210334A (es) 2021-07-14
WO2020128850A1 (en) 2020-06-25
SG11202105763SA (en) 2021-07-29
EP3898591A1 (en) 2021-10-27
IL284226A (en) 2021-08-31
JP2022513925A (ja) 2022-02-09
TWI743631B (zh) 2021-10-21
UY38517A (es) 2020-07-31
CN113272279A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CR20170367A (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CL2008002794A1 (es) Compuestos derivados de dihidropirimidina-2,4-(1h,3h)-diona; formas cristalinas, compuestos intermediarios; procedimiento de preparación de los compuestos intermediarios, composición farmacéutica; y su uso util para tratar hepatitis c en un mamífero.
PE20191496A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX2018008131A (es) Forma cristalina del inhibidor de la btk quinasa y metodo de preparacion de la misma.
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
AR084032A1 (es) Compuesto biciclico
AR106612A1 (es) Sales, formas cristalinas y composiciones farmacéuticas de 4-[2-(4-amino-piperidin-1-il)-5-(3-fluoro-4-metoxi-fenil)-1-metil-6-oxo-1,6-dihidro-pirimidin-4-il]-2-fluorobenzonitrilo como inhibidor de demetilasa 1 específica de lisina
BR112015007937A2 (pt) formas cristalinas de um inibidor de fator xia
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
NZ738836A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
PE20161437A1 (es) Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
MY194364A (en) Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use Thereof
BR112022002772A2 (pt) Formas cristalinas de análogos de quinolina e sais dos mesmos, composições e seus métodos para uso